Medexus Pharmaceuticals Inc (MDP) Price & Analysis

Compare

66 Followers

MDP Stock Chart & Stats

C$2.66

C$0.09(2.60%)

At close: Jan 08 4:00 PM EST

C$2.66

C$0.09(2.60%)

Day’s Range― - ―

52-Week RangeC$1.96 - C$5.56

Previous CloseN/A

Volume43.25K

Average Volume (3M)46.68K

Market Cap

C$86.24M

Enterprise ValueC$119.40M

Total Cash (Recent Filing)C$9.38M

Total Debt (Recent Filing)C$21.07M

Price to Earnings (P/E)123.1

Beta1.33

Next Earnings

Feb 11, 2026

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding32,420,060

10 Day Avg. Volume30,861

30 Day Avg. Volume46,683

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)0.83

Price to Sales (P/S)0.40

P/FCF Ratio2.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$6.00

Price Target Upside125.56% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market GrowthCanadian unit demand for Trecondyv grew 70% and the drug holds a significant market share in pediatric and adult alloHSCT markets in Canada.

Product LaunchPositive signs are seen in the launch of Grafapex.

Product SuccessGrafapex has shown early success in the U.S., with positive formulary inclusion from commercial payers and healthcare institutions.

Bears Say

Product SalesManagement has decided to no longer sell Gleolan in the U.S. as the product was not profitable.

Revenue DeclineTotal revenues decreased 4.6% year-over-year, a decline expected due mainly to generic pressure on Rupall.

Medexus Pharmaceuticals Inc News

Medexus Pharmaceuticals Inc.: Stable Growth and Promising Outlook Justify Buy Rating

Medexus Pharmaceuticals Inc, the Healthcare sector company, was revisited by a Wall Street analyst on November 14. Analyst...

1M ago

Medexus Secures New Credit Facilities and Plans Share Buyback

Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) has shared an announcement. Medexus Pharmaceuticals announced a new senior secured credit...

1M ago

Medexus Pharmaceuticals’ Earnings Call: GRAFAPEX Shines Amid Challenges

Medexus Pharmaceuticals (($TSE:MDP)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

Medexus Pharmaceuticals Reports Strong GRAFAPEX Performance Amidst Revenue Challenges

Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) just unveiled an announcement. Medexus Pharmaceuticals reported its fiscal Q2 2026 results,...

1M ago

Medexus Pharmaceuticals (MDP) Q2 Earnings Cheat Sheet

Medexus Pharmaceuticals (MDP) is scheduled to report 2nd quarter earnings on 11/12/2025, after the market closes. Regarding Q2...

1M ago

Medexus Pharmaceuticals to Discuss Q2 2026 Financial Results

The latest announcement is out from Medexus Pharmaceuticals Inc ( ($TSE:MDP) ). Medexus Pharmaceuticals has announced a conference...

2M ago

Medexus Pharmaceuticals Announces Election of Directors and Auditor Appointment

Medexus Pharmaceuticals Inc ( ($TSE:MDP) ) has shared an update. Medexus Pharmaceuticals held its virtual annual meeting of...

3M ago

Medexus Pharmaceuticals Earnings Call: Cautious Optimism Amid Challenges

Medexus Pharmaceuticals (($TSE:MDP)) has held its Q1 earnings call. Read on for the main highlights of the call....

4M ago

Buy Rating Affirmed for Medexus Pharmaceuticals Inc. Based on Solid Financial Performance and Strategic Positioning

Analyst David Martin PhD from Bloom Burton maintained a Buy rating on Medexus Pharmaceuticals Inc and keeping the...

4M ago

Medexus Pharmaceuticals Reports Strong Q1 2026 Results Driven by GRAFAPEX Launch

The latest update is out from Medexus Pharmaceuticals Inc ( ($TSE:MDP) ). Medexus Pharmaceuticals reported fiscal Q1 2026...

4M ago

MDP FAQ

What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?

Medexus Pharmaceuticals Inc lowest stock price was C$1.96 and its highest was C$5.56 in the past 12 months.

What is Medexus Pharmaceuticals Inc’s market cap?

Medexus Pharmaceuticals Inc’s market cap is C$86.24M.

When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?

Medexus Pharmaceuticals Inc’s upcoming earnings report date is Feb 11, 2026 which is in 53 days.

How were Medexus Pharmaceuticals Inc’s earnings last quarter?

Medexus Pharmaceuticals Inc released its earnings results on Nov 12, 2025. The company reported -C$0.014 earnings per share for the quarter, beating the consensus estimate of -C$0.03 by C$0.015.

Is Medexus Pharmaceuticals Inc overvalued?

According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medexus Pharmaceuticals Inc pay dividends?

Medexus Pharmaceuticals Inc does not currently pay dividends.

What is Medexus Pharmaceuticals Inc’s EPS estimate?

Medexus Pharmaceuticals Inc’s EPS estimate is -0.03.

How many shares outstanding does Medexus Pharmaceuticals Inc have?

Medexus Pharmaceuticals Inc has 32,420,060 shares outstanding.

What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?

Medexus Pharmaceuticals Inc reported an EPS of -C$0.014 in its last earnings report, beating expectations of -C$0.03. Following the earnings report the stock price went down -0.37%.

Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in TSE:MDP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Medexus Pharmaceuticals Inc Stock Smart Score

Underperform

Analyst Consensus

Moderate Buy

Average Price Target:
C$6.00 (125.56% Upside)

Technicals

Fundamentals

Return on Equity

0.87%

Trailing 12-Months

Asset Growth

4.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. (MDP) is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions for patients with rare diseases and unmet medical needs. Operating primarily in the pharmaceutical sector, Medexus specializes in a range of products, including hematology and autoimmune therapies, with a commitment to enhancing patient outcomes through effective treatments. The company is dedicated to expanding its portfolio through strategic partnerships and collaborations, as well as leveraging its expertise in drug development and commercialization.

Medexus Pharmaceuticals Inc (MDP) Earnings & Revenues

Historic Earnings Reports

MDP Stock 12 Month Forecast

Average Price Target

C$6.00

▲(125.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"C$1","4":"C$4","7":"C$7","2.5":"C$2.5","5.5":"C$5.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.5,4,5.5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,2.9353846153846157,3.190769230769231,3.4461538461538463,3.701538461538462,3.956923076923077,4.212307692307693,4.467692307692308,4.723076923076923,4.978461538461539,5.233846153846153,5.489230769230769,5.7446153846153845,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,2.9353846153846157,3.190769230769231,3.4461538461538463,3.701538461538462,3.956923076923077,4.212307692307693,4.467692307692308,4.723076923076923,4.978461538461539,5.233846153846153,5.489230769230769,5.7446153846153845,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.68,2.9353846153846157,3.190769230769231,3.4461538461538463,3.701538461538462,3.956923076923077,4.212307692307693,4.467692307692308,4.723076923076923,4.978461538461539,5.233846153846153,5.489230769230769,5.7446153846153845,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >